---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-084142"
form_type: "8-K"
ticker: "SEPN"
cik: "0001984086"
company_name: "Septerna, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:50:10.839887+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Septerna reports positive Phase 1 data for oral MRGPRX2 NAM SEP-631, plans Phase 2 in chronic spontaneous urticaria

## Summary
- SEP-631 well-tolerated; adverse event profile comparable to placebo across all doses studied
- Complete inhibition of icatibant-induced skin wheal formation at doses as low as 10 mg once daily
- Pharmacokinetic profile supports once-daily dosing with approximately 24-hour half-life
- Company plans Phase 2b trial in chronic spontaneous urticaria in the second half of 2026

## SEC filing metadata
- accession: 0001193125-26-084142
- form_type: 8-K
- ticker: SEPN
- cik: 0001984086
- company_name: Septerna, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1984086/000119312526084142/0001193125-26-084142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1984086/000119312526084142/d44190d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-084142
- JSON: https://secwatch.observer/filing/0001193125-26-084142.json
- Plain text: https://secwatch.observer/filing/0001193125-26-084142.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.